CAS: 42924-53-8; 4-(6-Methoxynaphthalen-2-yl)Butan-2-One

上下游产品

CAS号73356-31-7 4-羟基-4-(6-甲氧基-2... | CAS号598-32-3 3-丁烯-2-醇 | CAS号5111-65-9 2-溴-6-甲氧基萘 | CAS号127053-22-9 (E)-4-(6-甲氧基-2-... | CAS号3453-33-6 6-甲氧基-2-萘醛 | CAS号78-94-4 丁烯酮 | CAS号67-64-1 丙酮 | CAS号136579-95-8 methyl 3-(6-met... | CAS号917-64-6 甲基碘化镁 | CAS号32725-05-6 2-Naphthaleneet... | CAS号3453-33-6 6-甲氧基-2-萘醛 | CAS号65726-24-1 萘丁美酮醇 | CAS号68427-22-5 4-(6-hydroxynap...

6-甲氧基-2-萘甲醛置于palladium 10% On Activated Carbon,氢气,Sodium Hydroxide体系中,用 甲醇,水 作为反应溶剂,20.0~65.0 °C,101.33 Kpa 条件下,反应生成 萘丁美酮
参考文献:甲基酮作为卤代烷替代物:一种用于战略性官能团转化的脱酰卤化方法
标题:甲基酮作为卤代烷替代物:一种用于战略性官能团转化的脱酰卤化方法
摘要:卤代烷是获得多种官能团 (Fg) 的通用前体.由于其不稳定性,卤代烷替代物的开发对于复杂分子的合成具有重要的战略意义.鉴于常见烷基酮固有的稳定性和易于衍生化的特点,我们在此报告了一种脱酰卤化方法,可将各种甲基酮转化为相应的烷基氯,溴化物和碘化物.该反应通过形成芳香族副产物(即 1,2,4-三唑)来驱动的,其中使用n'-甲基吡啶甲酰肼酰胺 (Mpha) 形成前芳香族中间体,并使用卤素原子转移 (Xat) 试剂来猝灭反应.烷基中间体.该反应可有效地从多种甲基酮中反应生成伯烷基卤和仲烷基卤,并具有广泛的 Fg 耐受性.它还适用于复杂的天然产物衍生和含氟基材.此外,还实现了甲基酮一锅法转化为各种其他fg,以及通过脱酰卤化与烯烃和炔烃成环.此外,还证明了烷基碘的不寻常的迭代同系化.最后,机理研究揭示了脱酰碘化反应的一个有趣的双 Xat 过程,这可能具有超出本工作范围的影响.
DOI:10.1021/jacs.3C08176

专利信息

专利号:WO-2020230156-A1
优先权日:2019-05-10
标题 :A catalyst for one pot synthesis of nabumetone and process of preparation thereof
发明人：YADAV GANAPATI DADASAHEB; PISAL DEVENDRA SHRIRAM
权利人:YADAV GANAPATI DADASAHEB
摘要:The present invention relates to novel heterogeneous catalyst composition for selective synthesis of Nabumetone in one pot process and process to prepare the catalyst. The present invention provides a novel catalyst comprises of Lanthanum, Magnesium, and Nickel particles doped on specific type of silica support, preferably that the support is in amorphous nature. The catalyst is having bifunctional condensation and hydrogenation properties for one pot synthesis of Nabumetone comprising of: Nickel and Lanthanum-magnesium mixed oxide on support of mesoporous silica; Wherein 25 to 30 % w/w of Lanthanum-magnesium mixed oxide are entrapped in pores and surface of support is coated with 3 to 5% w/w Nickel with the result that it prevent the leaching of Lanthanum-magnesium mixed oxide in reaction medium and provides reusability of catalyst.

专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人：BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:US-RE37813-E
优先权日:1996-02-21
标题 :Process for the synthesis of nabumetone
发明人：CANNATA VINCENZO; BERTONI AMILCARE; BIANCHI STEFANO
权利人:HONEYWELL INT INC
摘要:New process for the synthesis of the antiinflammatory drug known as nabumetone that consists in reacting 2-acetyl-5-bromo-6-methoxynaphthalene with an alkyl acetate in presence of an alkaline alcoholate to get 4-(5-bromo-6-methoxy-2-naphthyl)-4-hydroxybut-3-en-2-one that by catalytic hydrogenation in a polar solvent and in presence of a base gives 4-(6-methoxy-2-naphthyl)butan-2-one known as nabumetone.

专利号:US-8546532-B2
优先权日:2008-04-17
标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
发明人：BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS
权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC
摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.

专利号:US-12264143-B2
优先权日:2020-12-17
标 题:Synthesis of cannabinoids and cannabinoid precursors, and related compounds, formulations, and methods of use
发明人：SAMMIS GLENN M; ROGGEN MARKUS
权利人:NALU BIO INC
摘要:Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

专利号:WO-2017100796-A1
优先权日:2015-12-11
标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人：WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.